Following the Target D trial, the speaker, a clinician, is now willing to discuss vitamin D testing and targeted supplementation with high-risk patients, something they would not have done previously.

Previous large vitamin D trials may have failed to show benefits because they gave a standard dose to everyone, including those who weren't deficient, rather than targeting a specific blood level.

The new Target D trial used a novel approach where the goal was to get patients' vitamin D blood level above 40 nanograms per milliliter and keep it there.

The Target D trial was not blinded, meaning patients and clinicians knew who was receiving treatment, which could introduce a significant placebo effect or other biases into the results.

In the Target D trial, targeting a specific vitamin D level in high-risk patients was associated with a 52% risk reduction for having another heart attack.

To reach the target blood level, many high-risk patients in the Target D trial started with a dose of 5,000 international units of vitamin D per day.

The Target D trial data hinted that aggressive vitamin D supplementation might be associated with a trend towards higher rates of heart failure hospitalization and strokes, suggesting potential trade-offs.